Shopping Cart 0
Cart Subtotal
AED 0

Oasmia Pharmaceutical AB (OASM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Oasmia Pharmaceutical AB (Oasmia Pharmaceutical) is a pharmaceutical company that develops drugs for human and veterinary oncology. The company's product portfolio consists of animal health products that include doxophos vet and paccal vet and human health products which include doxophos, paclical, docecal and OAS-19. Its paclical is a water-soluble formulation of paclitaxel and XR-17 is used as anti-cancer therapy for treatment of cancers such as breast cancer, lung cancer and ovarian cancer. The company develops products based on in-house research within nanotechnology and company patents. Oasmia Pharmaceutical provides services which includes organic synthesis, filling, analysis and freeze-drying, labeling and packaging. The company operates through research facility in Sweden. Oasmia Pharmaceutical is headquartered in Uppsala, Sweden.

Oasmia Pharmaceutical AB (OASM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Oasmia Pharma Acquires Cancer Project KB9520 from Karo Pharma 11

Private Equity 12

Nexttobe Acquires Additional Stake In Oasmia Pharma From Alceco International 12

Partnerships 13

Oasmia Pharma Enters into Marketing and Distribution Agreement with Hetero Drugs 13

Oasmia Pharma Enters Into Co-Marketing Agreement With Pharmasyntez For Paclical 14

Oasmia Pharma Enters Into Co-Development Agreement With Pharmasyntez 15

Equity Offering 16

Oasmia Pharma Plans to Raise up to USD25 Million in Public Offering of Securities 16

Oasmia Pharma Raises USD18.8 Million in Rights Offering of Shares 17

Oasmia Pharma Raises USD7.8 Million in Private Placement of Shares 18

Oasmia Pharma Raises USD2.2 Million in Private Placement of Shares 19

Oasmia Pharma Completes Underwriters Partial Exercise of Over-Allotment Option of Public Offering for USD10.8 Million 20

Oasmia Pharma Raises USD23.8 Million in Rights Offering of Shares 22

Oasmia Pharma Raises USD7 Million in Private Placement of Shares 24

Oasmia Pharma Completes Private Placement Of Shares For USD 11 Million 25

Oasmia Pharma Completes Rights Issue Of Shares For USD 19 Million 26

Debt Offering 27

Oasmia Pharma Raises USD3.9 Million in Private Placement of 8% Convertible Instruments 27

Oasmia Pharma Raises USD3.1 Million in Private Placement of 8% Convertible Instruments 28

Oasmia Pharma Raises USD3.3 Million in Private Placement of Convertible Instruments 29

Oasmia Pharmaceutical AB-Key Competitors 30

Oasmia Pharmaceutical AB-Key Employees 31

Oasmia Pharmaceutical AB-Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 33

Financial Announcements 33

Aug 31, 2018: Oasmia Pharmaceutical: Interim report for the period May-July 2018 33

Aug 31, 2018: Oasmia Pharmaceutical interim report for the period May-July 2018 37

Jun 08, 2018: Oasmia Pharmaceutical Year-end report for the financial year May 1, 2017-April 30, 2018 39

Mar 02, 2018: Oasmia Pharmaceutical: Interim report for the period May 2017-January 2018 44

Dec 01, 2017: Oasmia Pharmaceutical Interim report for the period May-October 2017 46

Sep 01, 2017: Oasmia Pharmaceutical: Interim report for the period May-July 2017 47

Jun 08, 2017: Oasmia Pharmaceutical: Year-end report for the financial year May 1, 2016-April 30, 2017 49

Corporate Communications 51

Oct 04, 2017: Oasmia Pharmaceutical Announces Resignation of its Chief Financial Officer 51

Appendix 52

Methodology 52

About GlobalData 52

Contact Us 52

Disclaimer 52


List Of Figure

List of Figures

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Oasmia Pharmaceutical AB, Deals By Therapy Area, 2012 to YTD 2018 9

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Oasmia Pharma Acquires Cancer Project KB9520 from Karo Pharma 11

Nexttobe Acquires Additional Stake In Oasmia Pharma From Alceco International 12

Oasmia Pharma Enters into Marketing and Distribution Agreement with Hetero Drugs 13

Oasmia Pharma Enters Into Co-Marketing Agreement With Pharmasyntez For Paclical 14

Oasmia Pharma Enters Into Co-Development Agreement With Pharmasyntez 15

Oasmia Pharma Plans to Raise up to USD25 Million in Public Offering of Securities 16

Oasmia Pharma Raises USD18.8 Million in Rights Offering of Shares 17

Oasmia Pharma Raises USD7.8 Million in Private Placement of Shares 18

Oasmia Pharma Raises USD2.2 Million in Private Placement of Shares 19

Oasmia Pharma Completes Underwriters Partial Exercise of Over-Allotment Option of Public Offering for USD10.8 Million 20

Oasmia Pharma Raises USD23.8 Million in Rights Offering of Shares 22

Oasmia Pharma Raises USD7 Million in Private Placement of Shares 24

Oasmia Pharma Completes Private Placement Of Shares For USD 11 Million 25

Oasmia Pharma Completes Rights Issue Of Shares For USD 19 Million 26

Oasmia Pharma Raises USD3.9 Million in Private Placement of 8% Convertible Instruments 27

Oasmia Pharma Raises USD3.1 Million in Private Placement of 8% Convertible Instruments 28

Oasmia Pharma Raises USD3.3 Million in Private Placement of Convertible Instruments 29

Oasmia Pharmaceutical AB, Key Competitors 30

Oasmia Pharmaceutical AB, Key Employees 31

Oasmia Pharmaceutical AB, Subsidiaries 32

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Oasmia Pharmaceutical AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Oasmia Pharmaceutical AB (Oasmia Pharmaceutical) is a pharmaceutical company that develops drugs for human and veterinary oncology. The company's product portfolio consists of animal health products that include doxophos vet and paccal vet and human health products which include doxophos, paclical, docecal and OAS-19. Its paclical is a water-soluble formulation of paclitaxel and XR-17 is used as anti-cancer therapy for treatment of cancers such as breast cancer, lung cancer and ovarian cancer. The company develops products based on in-house research within nanotechnology and company patents. Oasmia Pharmaceutical provides services which includes organic synthesis, filling, analysis and freeze-drying, labeling and packaging. The company operates through research facility in Sweden. Oasmia Pharmaceutical is headquartered in Uppsala, Sweden.

Oasmia Pharmaceutical AB (OASM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Oasmia Pharma Acquires Cancer Project KB9520 from Karo Pharma 11

Private Equity 12

Nexttobe Acquires Additional Stake In Oasmia Pharma From Alceco International 12

Partnerships 13

Oasmia Pharma Enters into Marketing and Distribution Agreement with Hetero Drugs 13

Oasmia Pharma Enters Into Co-Marketing Agreement With Pharmasyntez For Paclical 14

Oasmia Pharma Enters Into Co-Development Agreement With Pharmasyntez 15

Equity Offering 16

Oasmia Pharma Plans to Raise up to USD25 Million in Public Offering of Securities 16

Oasmia Pharma Raises USD18.8 Million in Rights Offering of Shares 17

Oasmia Pharma Raises USD7.8 Million in Private Placement of Shares 18

Oasmia Pharma Raises USD2.2 Million in Private Placement of Shares 19

Oasmia Pharma Completes Underwriters Partial Exercise of Over-Allotment Option of Public Offering for USD10.8 Million 20

Oasmia Pharma Raises USD23.8 Million in Rights Offering of Shares 22

Oasmia Pharma Raises USD7 Million in Private Placement of Shares 24

Oasmia Pharma Completes Private Placement Of Shares For USD 11 Million 25

Oasmia Pharma Completes Rights Issue Of Shares For USD 19 Million 26

Debt Offering 27

Oasmia Pharma Raises USD3.9 Million in Private Placement of 8% Convertible Instruments 27

Oasmia Pharma Raises USD3.1 Million in Private Placement of 8% Convertible Instruments 28

Oasmia Pharma Raises USD3.3 Million in Private Placement of Convertible Instruments 29

Oasmia Pharmaceutical AB-Key Competitors 30

Oasmia Pharmaceutical AB-Key Employees 31

Oasmia Pharmaceutical AB-Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 33

Financial Announcements 33

Aug 31, 2018: Oasmia Pharmaceutical: Interim report for the period May-July 2018 33

Aug 31, 2018: Oasmia Pharmaceutical interim report for the period May-July 2018 37

Jun 08, 2018: Oasmia Pharmaceutical Year-end report for the financial year May 1, 2017-April 30, 2018 39

Mar 02, 2018: Oasmia Pharmaceutical: Interim report for the period May 2017-January 2018 44

Dec 01, 2017: Oasmia Pharmaceutical Interim report for the period May-October 2017 46

Sep 01, 2017: Oasmia Pharmaceutical: Interim report for the period May-July 2017 47

Jun 08, 2017: Oasmia Pharmaceutical: Year-end report for the financial year May 1, 2016-April 30, 2017 49

Corporate Communications 51

Oct 04, 2017: Oasmia Pharmaceutical Announces Resignation of its Chief Financial Officer 51

Appendix 52

Methodology 52

About GlobalData 52

Contact Us 52

Disclaimer 52


List Of Figure

List of Figures

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Oasmia Pharmaceutical AB, Deals By Therapy Area, 2012 to YTD 2018 9

Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Oasmia Pharma Acquires Cancer Project KB9520 from Karo Pharma 11

Nexttobe Acquires Additional Stake In Oasmia Pharma From Alceco International 12

Oasmia Pharma Enters into Marketing and Distribution Agreement with Hetero Drugs 13

Oasmia Pharma Enters Into Co-Marketing Agreement With Pharmasyntez For Paclical 14

Oasmia Pharma Enters Into Co-Development Agreement With Pharmasyntez 15

Oasmia Pharma Plans to Raise up to USD25 Million in Public Offering of Securities 16

Oasmia Pharma Raises USD18.8 Million in Rights Offering of Shares 17

Oasmia Pharma Raises USD7.8 Million in Private Placement of Shares 18

Oasmia Pharma Raises USD2.2 Million in Private Placement of Shares 19

Oasmia Pharma Completes Underwriters Partial Exercise of Over-Allotment Option of Public Offering for USD10.8 Million 20

Oasmia Pharma Raises USD23.8 Million in Rights Offering of Shares 22

Oasmia Pharma Raises USD7 Million in Private Placement of Shares 24

Oasmia Pharma Completes Private Placement Of Shares For USD 11 Million 25

Oasmia Pharma Completes Rights Issue Of Shares For USD 19 Million 26

Oasmia Pharma Raises USD3.9 Million in Private Placement of 8% Convertible Instruments 27

Oasmia Pharma Raises USD3.1 Million in Private Placement of 8% Convertible Instruments 28

Oasmia Pharma Raises USD3.3 Million in Private Placement of Convertible Instruments 29

Oasmia Pharmaceutical AB, Key Competitors 30

Oasmia Pharmaceutical AB, Key Employees 31

Oasmia Pharmaceutical AB, Subsidiaries 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Oasmia Pharmaceutical AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.